"A Comprehensive Review on Targeted Drug Delivery Systems"

*Nikita D. Gidde[1], Pratiksha A. Mehtre[2], Supriya T. Londhe[3] Mahek K. Attar[4], Sajida S. Dhage[5]

[1]Shree Ambabai Talim Sanstha's Diploma in Pharmacy College, Miraj (MS) India 416410

[2,3,4,]Adarsh College of Pharmacy, Vita. (MS) India 415311

[5]Nootan College of Pharmacy, Kavathe Mahankal (MS) India 416405

Address for Correspondence:

Nikita D. Gidde

Assistant Professor

Shree Ambabai Talim Sanstha's

Diploma in Pharmacy College, Miraj (MS) India 416410

Abstract

Targeted drug delivery platforms are specialized systems created to transport therapeutic agents straight to diseased cells or tissues, thereby boosting treatment success while cutting down on unintended side effects. This review surveys state-of-the-art carrier technologies—such as liposomes, polymeric nanoparticles, dendrimers, gold nano shells, and stimuli-responsive vectors—and explores the mechanisms that enable their pinpoint accumulation. Key strategies include passive targeting via the enhanced permeability and retention effect, active targeting through ligand–receptor binding, and environmental triggers like pH shifts, temperature changes, or enzymatic activity.

Functionalization with antibodies, peptides, aptamers, or small molecules further sharpens tissue selectivity and permits controlled release profiles. These innovations enhance pharmacokinetics, lower systemic toxicity, and allow for reduced dosing, showing strong promise in oncology, neurological disorders, and inflammatory conditions. Persistent challenges involve refining targeting accuracy, ensuring biocompatibility over time, and developing scalable manufacturing processes under regulatory oversight. Despite these obstacles, targeted drug delivery remains a groundbreaking frontier in precision therapeutics.

Keywords: Drug targeting, Drug delivery, carriers, liposomes, Nanotechnology and Nanocarriers, Controlled Drug Release

INTRODUCTION

A targeted drug delivery system (TDDS) represents a significant advancement in pharmacology, addressing key limitations of conventional drug administration. Traditional methods often allow drugs to spread throughout the body, reaching both affected and healthy tissues. This widespread distribution can reduce the drug's effectiveness at the intended site and lead to unwanted side effects. In contrast, TDDS focuses the therapeutic agents specifically on the diseased cells, tissues, or organs, ensuring a higher concentration where it's needed most and sparing healthy areas.

The core concept behind targeted drug delivery systems (TDDS) is to enhance the bioavailability of drugs while minimizing toxicity, and ensuring controlled or sustained release. These systems employ advanced carriers—such as nanoparticles, liposomes, micelles, and antibody-drug conjugates (ADCs)—to transport medication directly to the specific site of action. TDDS proves particularly beneficial in treating conditions that affect vital organs, including cancers, tumors, heart diseases, and neurological disorders, where precise localization of the drug is crucial for effective therapy.

Personalized treatments and precision medicine have become increasingly prominent in the context of cancer and other complex diseases. As a result, innovations in targeted drug delivery systems (TDDS) are now viewed as a multidisciplinary field, integrating expertise from pharmaceutical sciences, molecular biology, materials science, and nanotechnology. This paper aims to examine both established TDDS technologies and emerging developments, while also addressing their current challenges and future potential within the rapidly advancing landscape of drug delivery. (1)

This paper provides a comprehensive overview of targeted drug delivery systems (TDDS), outlining the rationale behind their development. It identifies key limitations of conventional drug administration—such as systemic toxicity, poor bioavailability, and patient non-compliance—and emphasizes the need for more sophisticated strategies, especially in the context of advanced-stage cancers characterized by complex microenvironments and tissue heterogeneity.

TDDS mechanisms are categorized into passive and active approaches, with passive delivery leveraging the enhanced permeability and retention (EPR) effect, while active delivery relies on specific ligand-receptor interactions. The study highlights the ability of TDDS to cross biological barriers and improve pharmacokinetic and pharmacodynamic profiles. Crucially, the

article underscores the relevance of TDDS in modern therapeutic applications, presenting them as superior alternatives to traditional methods by enabling site-specific, controlled drug release. The authors advocate for interdisciplinary collaboration to address technical challenges and envision TDDS as foundational to the future of pharmaceutical innovation. (2)

Targeted drug delivery is a kind of smart drug delivery system which is miraculous in delivering the drug to a patient. This conventional drug delivery system is done by the absorption of the drug across a biological membrane, whereas the targeted release system is that drug is released in a dosage form. (3,4)

There are **several reasons why targeted drug delivery systems (TDDS) are employed**, including:

- Limited stability of certain drugs in biological environments
- Inefficient absorption of medications in traditional routes
- Rapid elimination due to a short half-life, reducing therapeutic effects
- Extensive distribution throughout the body, diluting drug concentration at the target site
- Lack of specificity in drug action, leading to unintended effects on healthy tissues
- A narrow therapeutic window, requiring precise dosing to avoid toxicity or ineffectiveness

An effective targeted drug delivery system (TDDS) should possess **several essential characteristics** to ensure optimal performance:

- It must be stable, non-toxic, compatible with bodily fluids, and biodegradable.
- Designed to release the drug exclusively at the intended site of action.
- Capable of regulating drug release at a controlled, pre-defined rate.
- The release rate should not interfere with the desired pharmacological effect.
- Minimize drug leakage during transit to the target location.
- Utilize carriers that are inert, biodegradable, or easily excreted by the body.
- The manufacturing process should be straightforward, efficient, and economical.

ADVANTAGES & DISADVANTAGES OF TARGETED DRUG DELIVERY SYSTEM (6,7)

Advantages	Disadvantages
The protocol of drug administration becomes simpler.	Rapid drug elimination from the body results in high dose frequency.
The toxicity of the drug is decreased by targeting a specific site.	The carrier of the targeted drug delivery system may result in the immune response.
Avoid the first-pass effect.	The drug delivery system is not localized at the tumor tissue for sufficient time.
The desired drug response can be reached by a small dose.	The diffusion and redistribution of released drugs
Improvement in the drug absorption from the target site.	The manufacturing, storage and administration of the targeted drug delivery system require high expertise in this field.
Drug targeting resulted in no peak and valley plasma concentration	Toxicity may be raised from drug deposition at the target site. & The stability of the product will be difficult to be attained.

TYPES OF CARRIERS APPLIED FOR DRUG TARGETING

Carrier systems are essential for achieving targeted drug delivery. They serve as vehicles designed to transport encapsulated drug molecules directly to specific sites within the body. These carriers ensure that the drug remains enclosed during transit and is released only at the target location, preventing unintended release in non-targeted areas. (5,8)



STRATEGIES FOR DRUG TARGETING

1. **Passive targeting:** Passive targeting usually refers to the drug delivery systems which target the drug to the systemic circulation.87 The passive targeting is done as a response from the body to the physicochemical properties of the drug or the drug delivery system which entrap the drug till reaching the target site. (9,10)
2. **Active targeting:** In this approach, targeted drug delivery is achieved by attaching specific recognition groups to the surface of the delivery system, which bind selectively to receptors present on the target cells. These recognition elements may include bio adhesive non-ionic surfactants, antibodies, or albumin proteins. Active targeting is further classified into three levels:

    - First-order targeting focuses on delivering drugs to a specific organ
    - Second-order targeting concentrates on targeting particular cells within that organ
    - Third-order targeting directs the drug into specific compartments inside the cells (11,12)

3. **Inverse targeting:** Inverse targeting is a strategy designed to prevent the passive absorption of drug delivery systems by the reticuloendothelial system (RES). This is achieved by temporarily suppressing RES activity—typically by injecting a high

volume of blank delivery vehicles or large dextran sulphate molecules, which saturate RES and dampen its immune response.

This technique proves especially beneficial for directing drugs to organs outside the RES. For example, researchers Balthasar and Fung successfully applied inverse targeting to deliver methotrexate to peritoneal tumors. (5)

4. **Ligand mediated targeting:** This type of drug targeting depends on the receptor uptake of natural low-density lipoprotein (LDL) particles and synthetic micro-emulsions of LDL particles covered with Apo proteins. (13)
5. **Physical targeting:** Physical targeting uses external stimuli to modify the drug carrier—such as heating, pH shifts, or electrical fields—so it homes in on a specific site. This approach shows strong promise for precisely delivering treatments to tumors and for gene-targeting applications. (6,14,15)
6. **Dual targeting:** The dual targeting mechanism involves a drug delivery system in which the carrier has a synergistic effect on the entrapped drug and hence increase the therapeutic effect. For example, a carrier molecule with antiviral activity when loaded with antiviral drug the therapeutic effect is enhanced. (16)
7. **Double targeting:** Double targeting merges two approaches—spatial and temporal—in a single system. Spatial targeting guides the carrier to the desired site, while temporal targeting controls when and how the drug is released once it arrives. (16)
8. **Combination targeting:** Combination targeting systems for site-specific protein and peptide delivery combine carriers, polymers, and molecularly specific homing devices. Conjugating proteins or peptides with natural polymers (like polysaccharides) or with synthetic polymers can change their inherent physical properties, and those changes critically influence how effectively the therapeutics localize to particular compartments, organs, or vascularized tissues. For example, hyaluronic acid conjugation can enhance uptake by CD44-expressing cells, while PEGylation prolongs circulation time. Homing ligands such as RGD peptides direct payloads to integrin-rich tissues, and antibodies can target specific cell receptors. By tuning polymer chemistry, molecular weight, conjugation sites, and ligand density, researchers can precisely control biodistribution and release kinetics for optimal therapeutic effect. (17)

FUTURE PERSPECTIVES

- **Emerging Technologies in Targeted Delivery:** Advanced drug delivery platforms are experiencing rapid innovation globally, driven by the need to improve therapeutic efficacy and patient compliance through precise control over where and when drugs act within the body. Nanoparticles—liposomes, dendrimers, polymeric and metallic particles—are at the forefront, acting as microscopic couriers that navigate complex biological barriers and home in on diseased tissues at the molecular level.

  Surface functionalization with targeting ligands (antibodies, peptides, aptamers) enables selective binding to receptors over-expressed on cancer, inflammatory or vascular targets, ensuring payloads accumulate exactly where needed. mart, stimuli-responsive systems represent the next leap. By engineering carriers that release drugs in response to pH shifts, enzymes, temperature changes or external triggers (light, magnetic fields), researchers can achieve on-demand dosing with minimal off-target toxicity. Integration of microfluidic fabrication and 3D printing is streamlining the production of these “intelligent” devices for clinical translation.

- **Personalized Medicine and Biologics:** The burgeoning fields of gene therapy, RNA-based treatments and therapeutic antibodies call for bespoke delivery solutions. Viral and non-viral vectors, exosomes, and lipid nanoparticles are being optimized to ferry genetic cargo past immune clearance and across tissue barriers, enabling corrective therapies for rare genetic disorders and cancers.

By coupling patient-specific biomarkers and real-time imaging feedback, future systems will dynamically adjust dosing, timing and release profiles to each individual’s disease signature. Machine learning models are being trained to predict optimal carrier compositions and dosing schedules, driving down development timelines and enhancing success rates.

KEY CHALLENGES AND REGULATORY LANDSCAPE

Despite the promise, several hurdles remain:

- **Biocompatibility and long-term safety:** Accumulation of nanomaterials in non-target organs may induce unforeseen toxicities, necessitating exhaustive preclinical and chronic-exposure studies.
- **Manufacturing and scalability:** Reproducing complex nanoscale architectures at commercial volumes while maintaining batch consistency is a major engineering challenge.
- **Regulatory frameworks:** Current guidelines are still evolving to assess hybrid products (device–drug combinations, cell-therapy vectors), prolonging approval pathways and increasing development costs.
- **Cost and access:** High manufacturing expenses risk limiting advanced therapies to affluent markets, highlighting the need for cost-effective production and equitable distribution strategies.

Beyond these current horizons, emerging areas to watch include micro- and nanorobots for active navigation, biomimetic carriers cloaked in cell membranes for immune evasion, and integrated theragnostic platforms that combine therapy with real-time diagnostic imaging. As interdisciplinary collaborations deepen among material scientists, engineers, biologists and clinicians, the next decade will likely usher in precision treatments that are safer, smarter and truly tailored to each patient.

CONCLUSION

Targeted drug delivery systems have transformed therapeutic approaches by directing active agents precisely to disease sites, thereby enhancing treatment efficacy and minimizing systemic toxicity. Innovations in carrier design—from ligand-functionalized nanoparticles and liposomes to stimuli-responsive materials—have expanded our ability to overcome biological barriers, achieve controlled release, and tailor dosing profiles to disease microenvironments.

Despite remarkable progress, key challenges remain. Ensuring long-term biocompatibility, achieving scalable manufacturing, and navigating evolving regulatory landscapes are critical hurdles on the path to widespread clinical adoption. Looking ahead, integration of personalized biomarkers, machine-learning–guided formulation design, and multifunctional theragnostic platforms promises to usher in a new era of truly bespoke therapies. By fostering interdisciplinary collaborations among materials scientists,

engineers, biologists, and clinicians, the next generation of targeted delivery systems will be smarter, safer, and finely tuned to each patient's unique disease signature.

REFERENCE

1. Ajay Kumar Singh, Targeted Drug Delivery Systems (TDDS): Literature Review, International Journal of Research Publication and Reviews, 2025: Vol 6, Issue 4, pp 3373-3380
2. A. Tewabe, A. Abate, M. Tamrie, A. Seyfu, and E. A. Siraj, "Targeted Drug Delivery — From Magic Bullet to Nanomedicine: Principles, Challenges, and Future Perspectives," Journal of Multidisciplinary Healthcare, vol. 14, pp. 1711–1724, Jul. 2021, doi: https://doi.org/10.2147/JMDH.S313968.
3. Muller RH, Keck CM; Challenges and solutions for the delivery of biotech drugs-a review of drug nanocrystal technology and lipid nanoparticles. Journal of Biotechnology, 2004; 113 (1–3): 151-170.
4. Allen TM, Cullis PR; Drug Delivery Systems: Entering the Mainstream. Science, 2004;303 (5665): 1818-1822.
5. Kousalya Prabahar1, Zahraa Alanazi2, Mona Qushawy3,4,* Targeted Drug Delivery System: Advantages, Carriers and Strategies, Indian Journal of Pharmaceutical Education and Research, 2021: 55(5); 346-353
6. Torchilin VP. Drug targeting. Eur J Pharm Sci. 2000;11:S81-91.
7. Yokoyama M. Drug targeting with nano-sized carrier systems. J Artif Organs. 2005;8(2):77-84.
8. Ruoslahti E. Drug targeting to specific vascular sites. Drug Discov Today. 2002;7(22):1138-43.
9. Hirsjarvi S, Passirani C, Benoit JP. Passive and active tumour targeting with nanocarriers. Curr Drug Discov Technol. 2011;8(3):188-96.
10. Jawahar N, Meyyanathan SN. Polymeric nanoparticles for drug delivery and targeting: A comprehensive review. Int J Health Allied Sci. 2012;1(4):217.
11. Bhargav E, Madhuri N, Ramesh K, Ravi V. Targeted drug delivery: A review. WJPPS. 2013;3(1):150-9.
12. Minko T, Dharap SS, Pakunlu RI, Wang Y. Molecular targeting of drug delivery systems to cancer. Curr Drug Targets. 2004;5(4):389-406.

13. Vyas SP, Sihorkar V. Endogenous carriers and ligands in non-immunogenic site-specific drug delivery. Adv Drug Deliv Rev. 2000;43(2-3):101-64
14. Weichselbaum RR, Kufe DW, Hellman S, Rasmussen HS, King CR, Fischer PH, et al. Radiation-induced tumour necrosis factor-α expression: Clinical application of transcriptional and physical targeting of gene therapy. Lancet Oncol. 2002;3(11):665-71.
15. Wagner E. Programmed drug delivery: Nanosystems for tumor targeting. Expert Opin Biol Ther. 2007;7(5):587-93.
16. Agnihotri J, Saraf S, Khale A. Targeting: New potential carriers for targeted drug delivery system. Int J Pharm Sci Rev Res. 2011;8(2):117-23.
17. Manoranjan Behera, A Comprehensive Review on Targeted Drug Delivery Systems, International Journal of Pharmaceutical Research and Applications,2023: 8(3); pp: 2914-2919